Clinical Efficacy Evaluation of Qingzhixiaoyan Decoction in the Treatment of the Hyperlipidemia Caused by Aromatase Inhibitor for the Postmenopausal Breast Cancer

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. All patients after surgical treatment were meet the pathological diagnostic criteria of breast cancer; The positive expression of estrogen receptor (ER) and / or progesterone receptor (PR) was confirmed by immunohistochemistry;
•2. Postmenopausal women;
•3. KPS score >= 60;
•4. The diagnosis of hyperlipidemia was in accordance with the relevant standards of Chinese guidelines for the prevention and treatment of dyslipidemia for adults;
•5. The diagnosis of TCM was in accordance with the standard of liver depression and phlegm coagulation syndrome in the diagnostic efficacy standard of TCM;
•6. The patients had good compliance, could understand the situation of this study and signed the informed consent, which was approved by the hospital ethics committee.

•1. Severe acute and chronic diseases, such as acute myocardial infarction, acute pancreatitis, stroke, heart failure, or familial dyslipidemia;
•2. Allergic to statins or known drugs;
•3. Language, mental retardation or other reasons can not cooperate with the study and follow-up;
•4. Other lipid-lowering drugs were taken in recent 4 weeks;
•5. Patients with other malignant tumors, severe hepatic or renal insufficiency;
•6. participated in other clinical trials in recent 3 months;
•7. Received chemoradiotherapy within 1 month.

发起方

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine